Comparative Pharmacology
Head-to-head clinical analysis: DORYX MPC versus ROBITET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX MPC versus ROBITET.
DORYX MPC vs ROBITET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
Robitussin (Robitet) is a combination product containing the antitussive dextromethorphan and the expectorant guaifenesin. Dextromethorphan acts centrally on the cough center in the medulla oblongata by increasing the threshold for coughing, primarily through sigma-1 receptor agonism and NMDA receptor antagonism. Guaifenesin increases the hydration of respiratory tract secretions, reducing mucus viscosity and facilitating expectoration.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
Tetracycline hydrochloride: 250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Terminal elimination half-life: 3.5 hours (2.6–4.8 h) in adults; prolonged to 6–12 h in severe renal impairment
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Renal: 30% unchanged; biliary/fecal: 50% as metabolites; remainder metabolized
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic